Clinical Neurological Society of America

CNSA is an organization of clinical & academic neurologists dedicated to neurology & the neurosciences.

[Clinical Neurological Society of America @NeuroAmerica]

To improve care for those with epilepsy, particularly those with difficult to diagnose and drug-resistant epilepsy, patients need more access to specialized care, including #EMUs.

Read more: https://t.co/3zTMr6V4zX

[Clinical Neurological Society of America @NeuroAmerica]

#AlzheimersDisease is distinguished from other forms of dementia by deposition and accumulation of two proteins in certain areas of the brain, such as:

🟢 Amyloid-beta
🟢 Tau

Read more: https://t.co/dpkqaC6tIp

[Clinical Neurological Society of America @NeuroAmerica]

📅 SAVE THE DATE for #CN27 in San Juan, Puerto Rico!

👀 More information on the conference coming soon.

🔗 Look for updates here: https://t.co/t8xgxLmZlJ

[Clinical Neurological Society of America @NeuroAmerica]

#DYK? #CAE was originally considered a “benign” type of epilepsy due to its high frequency of remission and because absence seizures are relatively easily controlled compared to seizures seen in other types of epilepsy.

Read more: https://t.co/5uQdzoIdCD

[Clinical Neurological Society of America @NeuroAmerica]

📅 SAVE THE DATE for #CN27 in San Juan, Puerto Rico!

👀 More information about the conference coming soon.

📄 In the meantime, view the #CN26 program: https://t.co/2m1LIGIGaX

[Clinical Neurological Society of America @NeuroAmerica]

Interested in becoming a member of CNSA? CNSA's mission is to improve clinical practice and patient care through education and thought leadership.

Join or renew here: https://t.co/iqs1mjRDAD

[Clinical Neurological Society of America @NeuroAmerica]

#DYK? #Alzheimers has three broad stages, including:

🟢 Preclinical
🟢 Mild-cognitive impairment
🟢 Dementia

Learn more: https://t.co/dpkqaC6tIp

[Clinical Neurological Society of America @NeuroAmerica]

The CIDP Ambassador Program, a collaboration between CNSA and Grifols, is an educational program on improving the recognition, diagnosis and treatment of #CIDP.

Applications for the 2026 program are opening soon!

Stay tuned & learn more: https://t.co/uduCgYZOpJ

[Clinical Neurological Society of America @NeuroAmerica]

#TB to #CN26 in Jupiter, Florida!

The event is designed to provide practicing neurologists with the most up-to-date information for the diagnosis and management of patients with neurologic conditions.

Keep a lookout for more information on #CN27!

[Clinical Neurological Society of America @NeuroAmerica]

CNSA's goal is to improve clinical practice and patient care through education and thought leadership.

Learn more about the society: https://t.co/3E9n1ejwob

[Clinical Neurological Society of America @NeuroAmerica]

The CIDP Ambassador Program, a collaboration between CNSA and Grifols, is an educational program on improving the recognition, diagnosis and treatment of #CIDP.

Applications for the 2026 program are opening soon!

Stay tuned & learn more: https://t.co/PZ3JdtqWrw

[Clinical Neurological Society of America @NeuroAmerica]

Raymond Scott Turner, MD, PhD, talks about the diagnostic tools in part two of CNSA's six-part video series about Alzheimer's disease.

Watch to learn more: https://t.co/375cDMaWkH

[Clinical Neurological Society of America @NeuroAmerica]

The underlying cause of #AIP is a genetic mutation in the pathway used to synthesize heme.

Watch to learn more about acute intermittent porphyria: https://t.co/7VUMOrpkD1

[Clinical Neurological Society of America @NeuroAmerica]

FDA's Breakthrough Therapy program facilitates the development of innovative medications that show the potential to provide substantially better outcomes than what patients experience with existing medications.

Read more: https://t.co/7eNNFp1Uuk

[Clinical Neurological Society of America @NeuroAmerica]

Marissa Natelson-Love, MD, talks about pre-diagnosis in part one of CNSA's six-part video series about Alzheimer's disease.

Watch to learn more: https://t.co/VBA31peKgo

[Clinical Neurological Society of America @NeuroAmerica]

CNSA's webinar, "Minimizing the Devastating Impact of Synucleinopathies," highlights the utility of biomarker testing in enabling early diagnosis and appropriate treatment of symptoms.

Watch to learn more: https://t.co/rCKRb6zI4t

[Clinical Neurological Society of America @NeuroAmerica]

#DYK? #Epilepsy is a neurological disorder that is characterized by the propensity for repetitive seizures. Specialized care, including epilepsy
monitoring units, or EMUs can help improve patients' lives.

Read more: https://t.co/3zTMr6V4zX

[Clinical Neurological Society of America @NeuroAmerica]

#AIP is a rare genetic disorder resulting from the deficiency in one of the enzymes in the heme biosynthetic pathway, leading to the accumulation of neurotoxic heme precursors.

Read more: https://t.co/JJPsiYvqJY

[Clinical Neurological Society of America @NeuroAmerica]

Today is #WorldParkinsonsDay!

#DYK? Parkinson's disease is associated with the abnormal collection of alpha-synuclein protein in cells in the central nervous system.

Read more in CNSA's white paper: https://t.co/wWLkY8Oy3l

[Clinical Neurological Society of America @NeuroAmerica]

#DYK? Although cases are rare, #RTT is still the second most identified cause of intellectual disability after Down syndrome.

Read more in CNSA's Rett syndrome white paper: https://t.co/B6h9HWW4uk